Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,200 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,200 shares of the company’s stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $237.66, for a total transaction of $285,192.00. Following the completion of the sale, the insider directly owned 142,486 shares in the company, valued at approximately $33,863,222.76. The trade was a 0.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.

Natera Stock Performance

NTRA opened at $231.48 on Friday. The firm has a market cap of $32.02 billion, a price-to-earnings ratio of -101.08 and a beta of 1.62. The firm’s 50-day simple moving average is $235.90 and its 200-day simple moving average is $193.29. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.26) earnings per share. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Morgan Stanley lifted their price objective on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Piper Sandler lifted their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. TD Cowen reissued a “buy” rating on shares of Natera in a report on Wednesday, January 7th. BNP Paribas Exane upgraded shares of Natera to a “hold” rating and set a $172.00 price objective for the company in a research report on Monday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Negative Sentiment: CFO Michael Burkes Brophy sold a total of 5,064 shares across Jan. 27–29 for roughly $1.19M (transactions at ~$240.53, $237.56 and $230.40); his holdings fell by ~3% but he still holds ~59k shares. CFO Form 4
• Negative Sentiment: CEO Steven L. Chapman sold 5,970 shares across Jan. 27–28 for roughly $1.43M (avg ~$237–240); his stake decreased ~1–2% and he still owns ~213k shares. CEO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold multiple tranches (combined ~3,925 shares, ~ $0.94M), each reducing holdings by under 1%. Fesko Form 4 Moshkevich Form 4

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC lifted its holdings in Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC lifted its position in Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth boosted its position in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of Natera in the second quarter valued at $298,000. Finally, Signaturefd LLC increased its stake in shares of Natera by 10.0% during the 2nd quarter. Signaturefd LLC now owns 1,620 shares of the medical research company’s stock worth $274,000 after purchasing an additional 147 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.